Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.
You may also be interested in...
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals
The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: